One year later, the patient serologic and radiographic studies revealed evidence of disease progression, with a rise in the Carcinoembryonic Antigen (CEA) tumor marker, and imaging revealed metastatic disease in the liver, omentum, and mesentery. This evidence concerns the gene CEACAM5 and metastatic neoplasm.